Thymosin Alpha-1 for Long COVID Immune Dysregulation

Candidate profile

Adults with documented prior COVID-19 infection experiencing persistent symptoms beyond 12 weeks — fatigue, cognitive dysfunction ("brain fog"), exercise intolerance, and immune markers consistent with dysregulation. Particularly relevant for patients with:

• Documented T-cell exhaustion markers (reduced CD8+ T-cell function, elevated PD-1 expression)
• Persistent inflammatory markers (elevated IL-6, CRP, or ferritin)
• Chronic fatigue unresponsive to rest and conventional management
• History of recurrent infections post-COVID (suggesting impaired immune surveillance)

Not appropriate as a standalone treatment for acute COVID-19 or for patients with active autoimmune conditions that could be exacerbated by immune modulation.

Approach

Thymosin alpha-1 (Tα1) as an immunomodulatory adjunct targeting the specific immune dysregulation pattern seen in long COVID — T-cell exhaustion, impaired NK cell function, and dysregulated inflammatory signaling. Unlike immunosuppressants, Tα1 aims to restore immune balance rather than suppress immune activity.

The rationale: long COVID immune pathology often involves exhausted T-cells that cannot clear residual viral reservoirs or restore normal immune homeostasis. Tα1 promotes T-cell maturation, enhances NK cell cytotoxicity, and increases regulatory T-cell function — addressing the dysfunctional immune state rather than simply dampening inflammation.

Protocol design

Primary peptide: Thymosin alpha-1, 1.6 mg subcutaneous

Frequency: 3 times per week (Monday, Wednesday, Friday) for the first 4 weeks, then 2 times per week for weeks 5–12

Duration: 12 weeks initial course, reassess for continuation

Route: Subcutaneous, typically abdominal

Optional adjuncts:

• KPV 250 mcg subcutaneous daily if significant GI involvement (gut inflammation is common in long COVID)
• BPC-157 250 mcg oral daily if intestinal permeability is suspected as a driver of systemic inflammation

Expected timeline

Weeks 1–2: Minimal symptomatic change. Immune remodeling is not rapid.

Weeks 3–4: Some patients report the first signs of improvement — slightly better energy, reduced frequency of "crash" days. Immune marker changes may begin appearing on bloodwork.

Weeks 5–8: Progressive improvement in fatigue, cognitive function, and exercise tolerance. T-cell subset analysis, if performed, may show improved CD4/CD8 ratios and reduced exhaustion markers.

Weeks 9–12: Continued consolidation. The goal is sustained improvement, not full resolution — long COVID recovery is typically gradual over months.

Concurrent requirements

• Structured activity pacing — overexertion causes post-exertional malaise (PEM) in long COVID. Activity should be gradually increased, not aggressively pushed
• Adequate nutrition — particularly zinc, vitamin D, selenium, and omega-3 fatty acids, which support the immune functions Tα1 is modulating
• Sleep optimization — immune remodeling occurs primarily during sleep. Address sleep disruption concurrently
• Stress management — chronic stress hormones (cortisol) impair T-cell function and counter Tα1's mechanism

Monitoring

Bloodwork (baseline, 4 weeks, 12 weeks):

• Complete blood count with differential (lymphocyte subsets)
• T-cell panel: CD4/CD8 ratio, CD4 and CD8 absolute counts
• NK cell count and function (if available)
• Inflammatory markers: CRP, IL-6, ferritin
• Optional: T-cell exhaustion markers (PD-1 expression on CD8+ cells)

Symptom tracking:

• Fatigue severity scale (FSS) — validated questionnaire
• Cognitive function — subjective rating and/or simple cognitive tests
• Exercise tolerance — 6-minute walk test or equivalent
• Frequency of PEM episodes per week

Important caveats

• Thymosin alpha-1 has decades of safety data in immunocompromised populations (hepatitis B, cancer immunotherapy adjunct), making it among the lower-risk research peptides for immune applications
• Long COVID is heterogeneous — not all patients have the same immune dysfunction pattern. Tα1 is most rationally applied when T-cell exhaustion or impaired innate immunity is documented
• This is an experimental application. No randomized controlled trial has tested Tα1 specifically for long COVID, though several are underway or planned
• Tα1 should complement, not replace, standard long COVID management (pacing, rehabilitation, sleep hygiene, nutritional optimization)